Trial record 19 of 45 for:    "ZAP70-related severe combined immunodeficiency" OR "Severe Combined Immunodeficiency"

Cord Blood Stem Cell Transplantation Study (COBLT)

This study has been completed.
Sponsor:
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier:
NCT00000603
First received: October 27, 1999
Last updated: January 18, 2008
Last verified: January 2008
  Purpose

To evaluate if HLA-mismatched, unrelated-donor umbilical cord blood stem and progenitor cell units (UCBU) offered a clinically acceptable alternative to matched unrelated-donor allogeneic bone marrow for transplantation with 180-day disease free survival as the endpoint. HLA typing was performed using DNA-base high resolution methods to determine HLA alleles. Patients with "true" HLA 3/6 and 4/6 matches were evaluated. In addition, a separate study in adults addressed the problem of limited cell dose and engraftment failure. The study was not planned as a randomized comparative clinical trial. Instead, it is a phase II/III efficacy study.


Condition Intervention Phase
Anemia, Aplastic
Fanconi Anemia
Hematologic Diseases
Leukemia
Neoplasms
Severe Combined Immunodeficiency
Hematopoietic Stem Cell Transplantation
Myelodysplastic Syndromes
Procedure: stem cell transplantation
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: September 1996
Study Completion Date: October 2007
Primary Completion Date: October 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   up to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Mothers of Infant-donors must complete a medical history form, have an uncomplicated delivery, and deliver at UCLA or Duke.

Patients are those who need a transplant but don't have a matched marrow donor or can't wait to find one.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000603

Sponsors and Collaborators
Investigators
Investigator: Shelly Carter The EMMES Corporation
Investigator: Joanne Kurtzberg Duke University
  More Information

Additional Information:
Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00000603     History of Changes
Other Study ID Numbers: 316
Study First Received: October 27, 1999
Last Updated: January 18, 2008
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Severe Combined Immunodeficiency
Anemia
Anemia, Aplastic
Neoplasms
Fanconi Anemia
Fanconi Syndrome
Hematologic Diseases
Immunologic Deficiency Syndromes
Leukemia
Myelodysplastic Syndromes
Preleukemia
Bone Marrow Diseases
Anemia, Hypoplastic, Congenital
Genetic Diseases, Inborn
DNA Repair-Deficiency Disorders
Metabolic Diseases
Kidney Diseases
Urologic Diseases
Renal Tubular Transport, Inborn Errors
Metabolism, Inborn Errors
Immune System Diseases
Neoplasms by Histologic Type
Precancerous Conditions
Infant, Newborn, Diseases

ClinicalTrials.gov processed this record on April 16, 2014